Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies—An Italian observational multicenter study
- 1 November 2016
- journal article
- research article
- Published by Elsevier in Epilepsy Research
- Vol. 127, 93-100
Abstract
No abstract availableKeywords
Funding Information
- Eisai s
This publication has 16 references indexed in Scilit:
- Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanelEpilepsia, 2015
- Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsyNeurology, 2015
- Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First ExperiencesNeuropediatrics, 2015
- Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307Epilepsia, 2014
- Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studiesEpilepsia, 2014
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Randomized phase III study 306Neurology, 2012
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- Antiepileptic drug therapy the story so farSeizure: European Journal of Epilepsy, 2010